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Background
Homozygous loss-of-function mutations in TREM2, encoding the triggering receptor expressed on myeloid cells 2 protein, have previously been associated with an autosomal recessive form of early-onset dementia.
Methods
We used genome, exome, and Sanger sequencing to analyze the genetic variability in TREM2 in a series of 1092 patients with Alz hei mer's disease and 1107 controls (the discovery set). We then performed a meta-analysis on imputed data for the TREM2 variant rs75932628 (predicted to cause a R47H substitution) from three genomewide association studies of Alzheimer's disease and tested for the association of the variant with disease. We genotyped the R47H variant in an additional 1887 cases and 4061 controls. We then assayed the expression of TREM2 across different regions of the human brain and identified genes that are differentially expressed in a mouse model of Alz hei mer's disease and in control mice.
Results
We found significantly more variants in exon 2 of TREM2 in patients with Alz heimer's disease than in controls in the discovery set (P = 0.02). There were 22 variant alleles in 1092 patients with Alz hei mer's disease and 5 variant alleles in 1107 controls (P<0.001). The most commonly associated variant, rs75932628 (encoding R47H), showed highly significant association with Alz hei mer's disease (P<0.001). Meta-analysis of rs75932628 genotypes imputed from genomewide association studies confirmed this association (P = 0.002), as did direct genotyping of an additional series of 1887 patients with Alz hei mer's disease and 4061 controls (P<0.001). Trem2 expression differed between control mice and a mouse model of Alz hei mer's disease.
lz hei mer's disease is the most common cause of dementia, typically presenting with a progressive loss of cognitive function and memory. It is a complex disorder with a strong genetic component. In the past, genetic studies have identified mutations in three genes -APP (encoding amyloid precursor protein), PSEN1 (encoding presenilin 1), and PSEN2 (encoding presenilin 2) -as the cause of disease in several families, most of whom have earlyonset disease. Expansions in C9orf72 are found in families with mixed types of disease. In late-onset disease, the most common form of Alz hei mer's disease, the ε4 allele of the apolipoprotein E gene (APOE) is the major known genetic risk factor. [1] [2] [3] [4] [5] Several genomic loci have been identified in genomewide association studies as low-risk factors for late-onset disease (implicating CLU, PICALM, CR1, BIN1, MS4A, CD2AP, CD33, EPHA1, and ABCA7 [6] [7] [8] [9] ).
Advances in sequencing techniques have allowed for the assessment of entire exomes and genomes. These techniques have the potential to identify rare mutations in families or patients in whom linkage analysis cannot be performed and to identify rare variants with moderate-to-strong effects in complex diseases.
Homozygous loss-of-function mutations in TREM2, encoding the triggering receptor expressed on myeloid cells 2 protein, have previously been associated with an autosomal recessive form of early-onset dementia presenting with bone cysts and consequent fractures called polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, or Nasu-Hakola disease. 10 We have recently identified homozygous TREM2 mutations in three Turkish patients presenting with a clinical phenotype associated with frontotemporal dementia and with leukodystrophy but without any bone-associated symptoms. 11 In addition, a genomewide meta-analysis pooling linkage results for late-onset Alz hei mer's disease identified eight linkage regions with nominally significant associations. One of these regions is on chromosome 6 (6p21.1-q15) and includes TREM2. 12 In this study, we wanted to find out whether heterozygous variants in TREM2 increase the risk of Alz hei mer's disease.
Me thods
Study Design
We performed exome or full-genome sequencing in samples from 281 patients with Alz hei mer's disease and 504 unaffected persons, with the latter including 175 elderly persons (>65 years of age) who were determined to be free of Alz hei mer's disease on neuropathological analysis. In the resulting sequence data, we analyzed six genes (APP, PS1, PS2, PGRN, MAPT, and TREM2) and noted a disproportionate number of variants in exon 2 of TREM2 in case samples. We then used polymerase-chain-reaction (PCR) amplification and Sanger sequencing to analyze exon 2 of TREM2 in samples from 811 patients with Alz hei mer's disease and 603 unaffected persons. In total, we analyzed samples from 1092 patients with Alzhei mer's disease and 1107 controls, all of whom were of European or North American descent (Table 1) .
To test for replication of the most strongly associated single-nucleotide polymorphism in our discovery set, we performed a meta-analysis of the summary statistics of several imputed genomewide association studies. In a second test of replication, we directly genotyped the R47H variant (encoding a substitution of histidine for arginine at position 47 of the protein) in patients with Alz hei mer's disease and in controls. To determine the level of TREM2 messenger RNA (mRNA) in human brain, we assayed TREM2 expression in samples obtained from 12 different brain regions in 137 controls. Using Affymetrix MOE 430 2.0 arrays, we compared the levels and pattern of Trem2 expression in the brains of a transgenic mouse model of Alz hei mer's disease 13 with that in control mice.
Exome Sequencing
Library preparation for next-generation sequencing was performed according to the TruSeq (Illumina) sample-preparation protocol. DNA libraries were then hybridized to exome-capture probes with NimbleGen SeqCap EZ Human Exome Library, version 2.0 (Roche NimbleGen), TruSeq (Illumina), or Agilent SureSelect Human All Exon Kit (Agilent Technologies). Each capture method covers the TREM2 locus. Exome-enriched libraries were sequenced on the HiSeq 2000 (Illumina).
We performed sequence alignment and variant calling against the reference human genome (UCSC hg19). Paired-end sequence reads (50 or 100 bp) were aligned with the use of the BurrowsWheeler aligner. 14 We performed duplicate read removal and format conversion and indexing using Picard (www.picard.sourceforge.net/index.shtml). We used the Genome Analysis Toolkit (GATK) to recalibrate base quality scores, perform local realignment around insertions and deletions, and call and filter variants. 15, 16 We used ANNOVAR software to annotate variants. 17 All protein-coding TREM2 variants in cases and controls were checked against established databases (1000 Genomes Project and dbSNP, version 134), and pathogenicity was predicted in silico with the use of Polymorphism Phenotyping, version 2 (PolyPhen-2). 18 
Genome Sequencing
We performed genome sequencing in samples obtained from 215 healthy persons in the Cache County Study on Memory in Aging, a series comprising 5092 residents of Utah who were followed for 12 years. We collected basic demographic information, family and medical histories, and results of multistage dementia-assessment screening for all participants. 19 The participants who were included in this study were found to be free of dementia on the basis of clinical dementia screening and evaluation, including the Clinical Dementia Rating Scale and Mini-Mental State Examination. All samples were sequenced with the use of Illumina HiSeq technology. Alignment was performed with the use of CASAVA software, 20 and variant calling was performed with the use of SAMtools 21 and GATK. 15, 16 
Meta-Analysis of Genomewide Association Studies
To evaluate the associated single-nucleotide polymorphism (SNP) rs75932628 (encoding the R47H protein variant) with the risk of Alz hei mer's disease, we used fixed-effects inverse-varianceweighted meta-analyses by combining the summary statistics from three studies: the European Alz hei mer's Disease Initiative Consortium (EADI), AddNeuroMed (ANM), and the Genetic and Environmental Risk for Alz hei mer's Disease Consor- Genotypes from the case-control series were analyzed by means of logistic regression with the use of an additive model either without covariates (as reported in the text) or with series, sex, age at diagnosis, and number of APOE ε4 alleles as covariates (Table S1 in the Supplementary Appendix).
TREM2 Expression in Human Brain
To assess the normal brain distribution of TREM2 expression, we used Affymetrix Exon 1.0 ST Arrays. Brain tissue from 137 neuropathologically confirmed controls was collected by the UK Brain Expression Consortium (UKBEC). Total RNA was isolated from 12 different brain regions per control and processed with the use of standard protocols (see the Supplementary Appendix for details).
Trem2 Expression in a Transgenic Mouse Model
TgCRND8 mice (a transgenic mouse model of Alz hei mer's disease) express a human APP695 transgene with two pathogenic mutations (KM670/671NL and V717F) under the regulation of the hamster prion protein promoter gene and were maintained in C3H/HeJ × C57BL/6J mice. (APP695 designates a particular transcript of APP). RNA was extracted from the brains of transgenic and nontransgenic littermate mice (with four mice per series, with profiles generated independently for each mouse) at the ages of 70, 80, and 150 days and was incubated on the MOE 430 2.0 array (Affymetrix) (see the Supplementary Appendix for additional details).
R e sult s
We found significantly more variants in exon 2 of TREM2 in patients with Alz hei mer's disease than in those without the disease (P = 0.02). In addition, we observed six variants (H157Y, R98W, D87N, T66M, Y38C, and Q33X) that were present in cases and not in controls in the discovery series and two variants that were present only in controls (N68K and L211P) ( Table 2) . Of these variants, D87N was significantly associated with disease (P = 0.02). We previously observed the T66M, Y38C, and Q33X variants in the homozygous state in patients with a frontotemporal dementia-like syndrome. Homozygous Q33X variants have also been identified in patients with Nasu-Hakola disease. The Q33X mutation almost certainly results in loss of function of TREM2 protein. Thus, we propose that the T66M and Y38C variants result in at least some loss of function. In aggregate, these three variants are more common in persons with Alz hei mer's disease than in unaffected persons (P = 0.01).
Of the variants in TREM2 associated with Alzhei mer's disease, the R47H variant showed the strongest association (P<0.001). On meta-analysis of three imputed data sets of genomewide association studies of Alz hei mer's disease (EADI, ANM, and GERAD) (Table S2 and Fig. S1 in the Supplementary Appendix), we observed significant association with disease (P = 0.002).
Given the limitation in imputing rare variants, we directly genotyped the R47H variant in 1994 patients with Alz hei mer's disease and 4062 controls (Table S1 in Analyses in participants not previously genotyped or imputed also showed a strong and highly significant association (odds ratio, 4.59; 95% CI, 2.49 to 8.46; P = 1.4×10 −7 ). Pathological examination of five brains with variants that have possibly pathogenic effects (Q33X, R47H, and D87N) revealed that all were Braak stage 6 (fully developed Alz hei mer's disease) and had typical findings with no distinguishing features. Two of the samples showed some mild Lewy-body disease, and one had documented TAR DNA-binding protein 43 (TDP-43) disease (Fig. 1) . In two cases, some mild white-matter abnormalities were observed, but these were not outside the range one would expect for a typical case of Alz hei mer's disease.
In human control brain, TREM2 was expressed widely, at high levels in white matter and substantial abundance in hippocampus and neocortex but at low levels in the cerebellum (Fig. S2 in the Supplementary Appendix). This expression pattern is partly consistent with the pathological features observed in both Nasu-Hakola disease and Alz hei mer's disease.
We assayed Trem2 expression in the brain tissue from TgCRND8 mice. 23 To capture changes reflecting the very earliest responses to APP misprocessing and accumulation of beta amyloid, rather than responses to late-stage tissue injury, we focused on time points at which the Alz heimer's disease-like phenotype was largely a biochemical accumulation of beta amyloid without obvious morphological changes (i.e., at 70 to 80 days). We also analyzed Trem2 expression during the phase of emerging disease and functional deficits (150 days). 23, 24 At the earlier time point, we observed 85 genes to be differentially expressed in the brains of mutant mice and controls (Table  S3 in the Supplementary Appendix). These genes comprised seven clusters. Clusters 1, 3, and 7 contained genes related to cholesterol or lipid metabolism, whose expression was coordinately altered from early time points (≤70 days). Cluster 5 included genes encoding complement factors, cytokines, and proinflammatory proteins, with changes in the expression of these factors at slightly later time points (>80 days). Genes encoding proteins that mediate vesicular trafficking genes did not appear to be differentially expressed (Tables S3 and S4 in the Supplementary Appendix).
To determine whether mRNA changes were reflected in changes in protein expression and to document the cell types involved, we assayed proteins in brain tissue from TgCRND8 mice, together with age-and sex-matched littermate controls, by means of Western blotting and immunohistochemical analysis. Suitable antibodies were not available for many proteins. Nevertheless, for proteins that could be assessed, the results were consistent with the mRNA data.
The expression of Trem2 mRNA was increased in TgCRND8 mice, as compared with nonTgCRND8 littermates (Table S4 in the Supplementary Appendix). This change, which is in agreement with a similar observation in another mouse transgenic model of Alz hei mer's disease, 25 was confirmed by means of Western blotting. We observed increased expression of Trem2 in large activated microglia (Fig. 2) . In wild-type mice, Trem2 is expressed in small cytoplasmic granules in the cytoplasm of most neurons in the cortex and other brain regions. The number and size of these granules in control mice were relatively constant during aging (mean [±SD] at 70 days, 6.7±0.5 granules per cell; at 90 days, 7.2±0.4; and at 150 days, 5.8±0.8). In contrast, in TgCRND8 mice, the average number of granules increased significantly as the amyloid disease emerged (at 70 days, 8.2±0.3 granules per cell; at 90 days, 22.4±0.6; and at 150 days, 15.0±0.3) (P = 0.01 for all comparisons). There was also a progressive increase in the diameter of granules (at 70 days, 0.4 μm; at 90 days, 0.6 μm; and at 120 days, 2.1 μm) (P = 0.01 for all comparisons). We observed Trem2 to be expressed in microglia surrounding the outer border of amyloid plaques, as reported previously in the APP23 mouse model 25 (Fig. 2) . Perhaps these changes represent a response to rising levels of beta amyloid in the TgCRND8 and APP23 mice, which, like all mouse models, develop prominent pathological findings associated with beta amyloid but no neurodegeneration. vation of immune responses in macrophages and dendritic cells. 10 As we have shown, TREM2 is expressed throughout the central nervous system and at particularly high concentrations in white matter. Homozygous loss-of-function mutations in TREM2 cause Nasu-Hakola disease (Online Mendelian Inheritance in Man number, 605086). Here we show that heterozygous rare variants, including those that cause Nasu-Hakola disease in the homozygous state, predispose to Alz hei mer's disease. Thus, we suggest that the reduced function of TREM2 is key to the pathogenic effect of these risk variants associated with Alz hei mer's disease. Trem2 is localized to microglia around plaques and neurons in the brains of TgCRND8 mice. In microglia, TREM2 is known to control two streams of signaling to regulate the reactive phenotype. One of these streams regulates phagocytosis. Increased expression of TREM2 on microglia is coupled to enhanced phagocytic pathways (which could be relevant to the removal of cell debris and the clearance of amyloid proteins in Alz heimer's disease) and promotion of the alternative activation state of microglia, which is thought to be protective. [26] [27] [28] The other signaling stream suppresses inflammatory reactivity and involves the repression of cytokine production and secretion. 28 TREM2 control of constitutive cytokine signaling may promote survival by prompting the secretion of tumor necrosis factor at levels that potentiate survival and repair pathways through tumor necrosis factor receptor 2 (TNFR2). Consistent with the results described in a previous study, 25 we have shown that the expression of TREM2 rises in parallel with a rise in cortical levels of beta amyloid. However, the dysregulation of expression that is induced by beta amyloid is relatively specific to TREM2. Other components of the same cascade, such as TYROBP, are not dysregulated. These data are consistent with a role for TREM2 as a gateway for controlling microglial responses. Compromised function of TREM2 is likely to have ramifications for the clearance of cell debris and possibly the removal of beta amyloid in Alz hei mer's disease. At the same time, relief of the TREM2 lock on cytokine levels, potentially effected by the TREM2 variants described here, may fuel inflammatory cascades, leading to a systemic inflammatory response and the incidental death of neurons. In an animal model of multiple sclerosis, blocking of Trem2 exacerbated disease symptoms, 27 whereas boosting of Trem2 signaling ameliorated them. 29 Variants of the gene CR1 have been implicated as risk factors for Alz hei mer's disease. 30 We have recently described functional data that support the control of microglial reactivity and the production of tumor necrosis factor by CR1 protein, suggesting parallel or convergent signaling streams with respect to those initiated by TREM2. 31, 32 Thus, if there are variants with reduced function in either of these pathways, the subsequent functional defects in microglial responses may show similar effects.
The approach we have taken shows that wholeexome sequencing is capable of identifying not only very rare mendelian causes of disease but also low-frequency variability with medium-effect sizes modulating disease development. Our data add to a growing list of disease associations 32 in which two diseases -one that is severe, has an early onset, and is caused by homozygous loss-offunction mutations and the other that has a late onset with susceptibility caused by heterozygous loss-of-function variants -had previously been thought to be unrelated. 32 We and others have predicted that heterozygous loss-of-function variants may represent a substantial component of risk for common late-onset diseases. 32, 33 Our findings support this hypothesis, and we believe additional loss-of-function variants will be identified as risk factors for Alz hei mer's disease and other late-onset complex disorders. We thank the controls, the patients, and their families; the National Cell Repository for Alz hei mer's Disease and the Human Genetics Resource Center DNA and Cell Line Repository; the National Heart, Lung, and Blood Institute Grand Opportunity (GO) Exome Sequencing Project and its ongoing studies, which produced and provided exome variant calls for comparison; the 1000 Genomes Project; and the MRC London Neurodegenerative Diseases Brain Bank and the Manchester Brain Bank from Brains for Dementia Research for providing samples and pathological diagnosis.
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